These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21391610)

  • 41. Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).
    Norman P
    Expert Opin Ther Pat; 2014 Sep; 24(9):979-91. PubMed ID: 24990480
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Itk inhibitors: a patent review.
    Lo HY
    Expert Opin Ther Pat; 2010 Apr; 20(4):459-69. PubMed ID: 20218931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
    Hollick JJ; Rigoreau LJ; Cano-Soumillac C; Cockcroft X; Curtin NJ; Frigerio M; Golding BT; Guiard S; Hardcastle IR; Hickson I; Hummersone MG; Menear KA; Martin NM; Matthews I; Newell DR; Ord R; Richardson CJ; Smith GC; Griffin RJ
    J Med Chem; 2007 Apr; 50(8):1958-72. PubMed ID: 17371003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases.
    von Bonin A; Rausch A; Mengel A; Hitchcock M; Krüger M; von Ahsen O; Merz C; Röse L; Stock C; Martin SF; Leder G; Döcke WD; Asadullah K; Zügel U
    Exp Dermatol; 2011 Jan; 20(1):41-7. PubMed ID: 21158938
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
    Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
    J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
    Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors.
    Bandarage U; Hare B; Parsons J; Pham L; Marhefka C; Bemis G; Tang Q; Moody CS; Rodems S; Shah S; Adams C; Bravo J; Charonnet E; Savic V; Come JH; Green J
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5191-4. PubMed ID: 19632115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design and synthesis of 6-oxo-1,6-dihydropyridines as CDK5 inhibitors.
    Kaller MR; Zhong W; Henley C; Magal E; Nguyen T; Powers D; Rzasa RM; Wang W; Xiong X; Norman MH
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6591-4. PubMed ID: 19864130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.
    El-Deeb IM; Park BS; Jung SJ; Yoo KH; Oh CH; Cho SJ; Han DK; Lee JY; Lee SH
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5622-6. PubMed ID: 19700314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fragment Molecular Orbital Method Applied to Lead Optimization of Novel Interleukin-2 Inducible T-Cell Kinase (ITK) Inhibitors.
    Heifetz A; Trani G; Aldeghi M; MacKinnon CH; McEwan PA; Brookfield FA; Chudyk EI; Bodkin M; Pei Z; Burch JD; Ortwine DF
    J Med Chem; 2016 May; 59(9):4352-63. PubMed ID: 26950250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
    Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C
    J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: lead optimization.
    Siu T; Kumarasinghe SE; Altman MD; Katcher M; Northrup A; White C; Rosenstein C; Mathur A; Xu L; Chan G; Bachman E; Bouthillette M; Dinsmore CJ; Marshall CG; Young JR
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1466-71. PubMed ID: 24582987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2009 Jan; 17(1):284-94. PubMed ID: 19010686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
    Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
    Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors.
    Kashem MA; Nelson RM; Yingling JD; Pullen SS; Prokopowicz AS; Jones JW; Wolak JP; Rogers GR; Morelock MM; Snow RJ; Homon CA; Jakes S
    J Biomol Screen; 2007 Feb; 12(1):70-83. PubMed ID: 17166826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
    Tsou HR; MacEwan G; Birnberg G; Grosu G; Bursavich MG; Bard J; Brooijmans N; Toral-Barza L; Hollander I; Mansour TS; Ayral-Kaloustian S; Yu K
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2321-5. PubMed ID: 20188552
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.
    Aronov AM; Tang Q; Martinez-Botella G; Bemis GW; Cao J; Chen G; Ewing NP; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Markland W; Namchuk MN; Nanthakumar S; Poondru S; Straub J; ter Haar E; Xie X
    J Med Chem; 2009 Oct; 52(20):6362-8. PubMed ID: 19827834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.